Atalanta Therapeutics: Raises $110M in Series A Funding

  • Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative diseases, raised $110m in Series A funding
  • The financing was provided exclusively by F-Prime Capital
  • Additionally, Atalanta announced strategic collaborations with Biogen (Nasdaq: BIIB) and Genentech, a member of the Roche Group
  • As part of the strategic collaboration with Biogen, Atalanta will develop RNAi therapeutics for multiple targets
  • The company will be eligible to receive development and milestone payments on these programs as well as royalty payments on any resulting products
  • The strategic collaboration with Genentech involves the development of RNAi therapeutics for multiple CNS targets for neurodegenerative diseases
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Truist Pilots Zelle Bill Payments, Strengthening Digital Banking Services

New pilot program aims to simplify bill payments through Zelle for customers.Highlights: Truist launches pilot program for Zelle...

ACI Worldwide Strengthens Payment Solutions with Cloud-Native Platform

New platform enhances support for eight U.S. payment networks.Highlights: ACI Worldwide launches a cloud-native payment platform.The platform supports...

LendingClub Rebrands as Happen Bank, Strengthens Digital Banking Services

The transformation aims to enhance customer engagement and streamline services.Highlights: LendingClub officially rebrands to Happen Bank.The rebrand focuses...

NatWest Strengthens Venture Banking by Partnering with AWS

Collaboration will enhance digital services for startups and scale-ups.Highlights: NatWest partners with AWS to launch a new venture...